(AOF) – OSE Immunotherapeutics announces the publication of the latest results on the pro-resolving monoclonal antibody OSE-230, an innovative new approach in the resolution of severe and chronic inflammation, in the journal “Frontiers in Immunology”. Through activation of ChemR23, OSE-230 reprograms tumor-associated macrophage cells. The ChemR23 receptor strongly controls the macrophage phenotype and its activation by OSE-230 results in significant remodeling of the immune tumor microenvironment.
“We are very pleased with this publication of OSE-230 in ‘Frontiers in Immunology’, a leading journal in its field which publishes major discoveries in immunology”, declared Aurore Morello, Director of Research & Development of OSE Immunotherapeutics. “These data make OSE-230 a first-in-class candidate for more advanced preclinical studies and pave the way for many chronic inflammatory disease indications, thanks to the product’s significant strengths over immunosuppressive treatments.”
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.